Key points are not available for this paper at this time.
To describe overall survival, time to castration resistance and castration resistance-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide in a US oncology network.
Lowentritt et al. (Mon,) studied this question.